TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 AMD
Advanced Micro Devices
-- 119.210 OXY
Occidental Petroleum
-- 47.130 
Vaccine that nobody is talking about has potential…
I notice that when people talk about Valneva, you hear endless talk about Lyme & Chikungunya, but there is almost no talk about SV4, a tetravalent bioconjugate vaccine candidate against shigellosis that is entering Phase 2. It seems that most of the talk regarding this centers around children in third world underdeveloped countries, but there is a possible huge market if it gets worked into the standard childhood vaccine schedule required for public school attendance in the United States. Granted, there are quite a few horses in this race (including several developed by the National Institutes of Health themselves), but if SV4 can make it past the gauntlet early and without production complications or undiscovered interactions and side effects, it could make a lot of money based on sheer volume of sales, as most parents hate having bouts of diarrhea spread throughout the entire household.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment